CSA Still Demands Rigour, Applied Where The Risk Is

There's a version of CSA that circulates in quality departments as good news. FDA released guidance. Documentation requirements are going down. Testing is going to get easier. Some organizations have started treating Computer Software Assurance as permission to do less.

That reading tends to surface later as audit findings.

CSA can reduce unnecessary documentation, and it moves focus away from scripted testing for its own sake. That reduction only applies where a risk assessment justifies it. Where risk is present, the expectation for evidence stays the same. If anything, making those calls correctly takes more discipline than traditional CSV did.

We've been working inside this framework since before the guidance was formalized. The risk-based approach was always the underlying intent of validation. CSA made that intent explicit and gave organizations a structured way to act on it. The bar for proving your process is in control stayed where it was.

Where the misconception comes from

The confusion makes sense. When organizations hear that CSA allows greater use of unscripted testing and encourages assurance activities commensurate with risk, it sounds like relief. In the right context, it is.

The problem is that many organizations hear "reduced documentation" and stop there. They skip the risk assessment that determines which documentation can be reduced and which can't. They apply the conclusion without doing the analysis that earns it.

Suresh made this point directly in a recent seminar, drawing on his own experience setting up validation departments early in his career. Validation was never supposed to be about creating large volumes of documentation. The intent was always to assess impact, identify risk, and test where it mattered. Over time, the industry got very good at producing documents and lost focus on the question those documents were meant to answer: does this system, as used, pose a risk to the product?

CSA brings that question back to the center, and the documentation follows from the answer.

One note on scope. FDA wrote the CSA guidance for medical device production and quality system software. Many pharma and biotech teams apply the same risk-based principles, and the logic carries across. The guidance itself is non-binding, and it works alongside your own procedures rather than replacing them.

What the CSA guidance expects

Under CSA, assurance activities begin by understanding risks. That assessment of product quality, patient safety or process integrity identifies the level of assurance that is appropriate to the risk.

The first scenario is that the function poses meaningful risk to product quality or patient safety. Testing is needed, you collect evidence, and a more rigorous level of testing and objective evidence is appropriate. The focus is demonstrating that the identified risk is adequately controlled.

The second is that the function poses some risk, but not enough to call for a full scripted protocol of your own. Here the guidance allows lighter assurance. You might reference vendor documentation, such as unit test records or design specifications, or run unscripted testing. The risk still gets addressed, through a different route. The assurance activity is proportionate to the risk.

The third is that the function poses no meaningful risk to the product or process. The assessment may demonstrate that additional testing is not warranted. You document the assessment, record the conclusion, and move on.

In practice, CSA redirects the work of validation. Instead of executing tests uniformly across every system function, you put your effort into risk assessment first, then focus on assurance activities where the assessment tells you they provide the most value. Total documentation volume may go down. The rigor you apply to the areas that matter does not.

Risk assessment is the engine

Risk assessment is the part of CSA that organizations can easily under-invest in. The whole approach runs on it, and it takes real critical thinking to do well.

Many risk models ask two questions. First, what's the likelihood that this function could fail in a way that affects the product or process? Second, if it did fail, what would the impact be? Together, these risk factors establish a level of risk that informs that appropriate assurance activities.

Those questions are demanding because the answers aren't generic. They depend on how the system is configured in your environment, what it connects to, what data it handles, and what role it plays in the production or quality process. A function that's low risk in one organization may be high risk in another because the process context is different.

That came up in a seminar question recently. An attendee asked how Validator supports CSA in daily validation work. The answer started with the risk assessment module. Because the module is configurable, each organization can build its own risk model into the system, with its own scoring criteria, thresholds, and methodology. Some organizations use FMEA. Some use qualitative models. Some use quantitative scoring. The platform accommodates all of them, so the organization doesn't have to change how it thinks about risk.

When a validation practitioner runs a risk assessment inside Validator, the system applies the configured model to help determine the appropriate assurance activities for each function. Higher-risk functions require greater assurance, rigor and objective evidence. Lower-risk functions may justify less formal testing or reliance on other appropriate evidence. Where the assessment determines that additional testing isn't warranted, that conclusion and its rationale are documented. The system applies the organization's own criteria consistently, helping ensure the resulting assurance requirements and rationale are documented and traceable.

How your internal QA team sets the standard

A big part of CSA comes down to who sets the standard inside your organization.

FDA provides guidance. It describes the framework, the intent, and the expectations. Applying that framework to your specific systems, processes, and organizational context requires your organization to establish and document its own risk-based approach, typically under the governance of your internal QA team.

Your QA team reads the guidance, decides how it applies to your environment, and establishes the procedures that govern validation in your organization. Those procedures define the risk model you use, the threshold that separates high from low risk, the evidence each level needs, and the documentation expected at the end of a validation. Every validation practitioner in your organization works within that framework.

That's why a digital validation platform you can configure to your QA team's standards matters so much. Once QA has defined the risk model, the evidence requirements, and the workflow, the platform should apply those definitions consistently. The critical thinking happens when QA builds the model and when the practitioner assesses each function. After that, the practitioner shouldn't have to reinterpret the organization's methodology each time a risk conclusion is reached. The system can guide the required assurance activities based on the criteria QA has established.

That's what consistent compliance looks like across a team, across sites, and over time. The QA interpretation lives in the system, and every validation runs through the same logic.

What a CSA-configured system does differently

When Validator is configured for a CSA approach, the risk assessment drives the validation from within.

As your team enters and assesses requirements, the system applies the configured risk model to each one. The outcome of that assessment shapes the validation record for that requirement. High-risk requirements generate a full testing requirement with evidence fields and pass/fail logic. Lower-risk requirements may allow other forms of assurance, such as a reference field for linking appropriate vendor documentation. Where the organization's risk model determines that additional testing isn't warranted, the system documents that conclusion and captures the supporting rationale.

If a practitioner tries to move forward without completing what the risk level calls for, the system stops them. If evidence is required and nobody has attached it, the step can't be marked complete. If an incident is still open, the summary report can't be released. The compliance logic runs as an embedded control throughout execution.

Compare that with a system where a practitioner completes a risk assessment form, notes the conclusion, and then runs the validation independently. In a CSA-configured platform, the risk conclusion and the validation execution are connected, so the organization's risk-based methodology carries directly into the assurance activities that follow.

The documentation burden was never the point

The validation professionals who built the original frameworks were trying to demonstrate that a process was in control. The documents were the evidence that supported the conclusion.

CSA addresses decades of drift toward documentation for its own sake. It asks organizations to start by asking whether a system poses a risk to their process, product quality, or patient safety then scale the assurance activities accordingly.

For organizations that do this work carefully, with a properly configured risk model and a platform that applies their methodology consistently, the result can be a leaner validation program that stands up well with regulators. What’s left is the documentation that matters. Every piece of evidence in the record is there because a risk assessment said it needed to be.

That's what CSA is designed to produce: the appropriate rigour, applied where it belongs.

Frequently Asked Questions